BACKGROUND: After the successful treatment of periprosthetic joint infection (PJI), patients may present with degenerative joint disease in another joint with symptoms severe enough to warrant arthroplasty. However, it is not known whether patients with a history of treated PJI at one site will have an increased risk of PJI in the second arthroplasty site. QUESTIONS/PURPOSES: The primary objective of this study is to determine if there is a difference in the risk of developing a PJI after a second total hip arthroplasty (THA) or total knee arthroplasty (TKA) in patients who have had a previous PJI at another anatomic site compared with patients who have had no history of PJI. The secondary objective is to determine other potential risk factors that may predict PJI at the site of the second arthroplasty. METHODS: A retrospective matched cohort study was performed to identify all patients at four academic institutions successfully treated for PJI who subsequently underwent a second primary THA or TKA (n = 90), constituting our study group. Patients were matched (one-to-one) to control subjects who had no history of PJI after their first arthroplasty (n = 90); they were matched based on age, sex, diabetic status, BMI, American Society of Anesthesiologists, institution, joint of interest, and year of surgery (± 2 years). We compared the case and control groups to determine whether a prior infection increased the relative risk of a subsequent PJI at another anatomic site. To identify other potential risk factors for subsequent PJI, a subgroup univariate analysis of our study group (n = 90) was performed. To identify other potential risk factors for subsequent PJI, a subgroup univariate analysis of our study group (n = 90) was performed. RESULTS: Patients with a history of PJI had a greater risk of developing PJI in a subsequent THA or TKA (10 of 90 versus zero of 90 in the control group; relative risk, 21.00; 95% confidence interval [CI], 1.25-353.08; p = 0.035). Excluding PJI, we identified no other factors associated with a second joint infection. In patients with a history of PJI, a second PJI occurred more frequently in female patients (female: nine of 10 [90%] versus female: 40 of 80 [50%]; odds ratio [OR], 8.83; 95% CI, 1.13-403.33; p = 0.02) and in those whose initial infection was a staphylococcal species (subsequent PJI seven of 10 [70%] versus no subsequent PJI 28 of 80 [35%]; OR, 4.26; 95% CI, 0.89-27.50; p = 0.04). CONCLUSIONS: A history of PJI predisposes patients to subsequent PJI in primary THA or THA. Patients and surgeons must be aware of the higher risk of this devastating complication before proceeding with a second arthroplasty. LEVEL OF EVIDENCE: Level III, prognostic study.
BACKGROUND: After the successful treatment of periprosthetic joint infection (PJI), patients may present with degenerative joint disease in another joint with symptoms severe enough to warrant arthroplasty. However, it is not known whether patients with a history of treated PJI at one site will have an increased risk of PJI in the second arthroplasty site. QUESTIONS/PURPOSES: The primary objective of this study is to determine if there is a difference in the risk of developing a PJI after a second total hip arthroplasty (THA) or total knee arthroplasty (TKA) in patients who have had a previous PJI at another anatomic site compared with patients who have had no history of PJI. The secondary objective is to determine other potential risk factors that may predict PJI at the site of the second arthroplasty. METHODS: A retrospective matched cohort study was performed to identify all patients at four academic institutions successfully treated for PJI who subsequently underwent a second primary THA or TKA (n = 90), constituting our study group. Patients were matched (one-to-one) to control subjects who had no history of PJI after their first arthroplasty (n = 90); they were matched based on age, sex, diabetic status, BMI, American Society of Anesthesiologists, institution, joint of interest, and year of surgery (± 2 years). We compared the case and control groups to determine whether a prior infection increased the relative risk of a subsequent PJI at another anatomic site. To identify other potential risk factors for subsequent PJI, a subgroup univariate analysis of our study group (n = 90) was performed. To identify other potential risk factors for subsequent PJI, a subgroup univariate analysis of our study group (n = 90) was performed. RESULTS:Patients with a history of PJI had a greater risk of developing PJI in a subsequent THA or TKA (10 of 90 versus zero of 90 in the control group; relative risk, 21.00; 95% confidence interval [CI], 1.25-353.08; p = 0.035). Excluding PJI, we identified no other factors associated with a second joint infection. In patients with a history of PJI, a second PJI occurred more frequently in female patients (female: nine of 10 [90%] versus female: 40 of 80 [50%]; odds ratio [OR], 8.83; 95% CI, 1.13-403.33; p = 0.02) and in those whose initial infection was a staphylococcal species (subsequent PJI seven of 10 [70%] versus no subsequent PJI 28 of 80 [35%]; OR, 4.26; 95% CI, 0.89-27.50; p = 0.04). CONCLUSIONS: A history of PJI predisposes patients to subsequent PJI in primary THA or THA. Patients and surgeons must be aware of the higher risk of this devastating complication before proceeding with a second arthroplasty. LEVEL OF EVIDENCE: Level III, prognostic study.
Authors: Yunchao Shao; Chi Zhang; Kory D Charron; Steven J Macdonald; Richard W McCalden; Robert B Bourne Journal: J Arthroplasty Date: 2013-12 Impact factor: 4.757
Authors: Benjamin Zmistowski; Matthew W Tetreault; Pouya Alijanipour; Antonia F Chen; Craig J Della Valle; Javad Parvizi Journal: J Arthroplasty Date: 2013-04-12 Impact factor: 4.757
Authors: S Mehdi Jafari; David S Casper; Camilo Restrepo; Benjamin Zmistowski; Javad Parvizi; Peter F Sharkey Journal: J Arthroplasty Date: 2012-03-03 Impact factor: 4.757
Authors: Paul H Yi; Rachel M Frank; Elliott Vann; Kevin A Sonn; Mario Moric; Craig J Della Valle Journal: Clin Orthop Relat Res Date: 2015-01 Impact factor: 4.176
Authors: James D Whitehouse; N Deborah Friedman; Kathryn B Kirkland; William J Richardson; Daniel J Sexton Journal: Infect Control Hosp Epidemiol Date: 2002-04 Impact factor: 3.254
Authors: S M Javad Mortazavi; Justin Schwartzenberger; Matthew S Austin; James J Purtill; Javad Parvizi Journal: Clin Orthop Relat Res Date: 2010-08 Impact factor: 4.176
Authors: Mike B Anderson; Karen Curtin; Jathine Wong; Christopher E Pelt; Christopher L Peters; Jeremy M Gililland Journal: J Bone Joint Surg Am Date: 2017-06-07 Impact factor: 5.284
Authors: Beverly L Hersh; Neel B Shah; Scott D Rothenberger; Jason P Zlotnicki; Brian A Klatt; Kenneth L Urish Journal: J Arthroplasty Date: 2019-06-28 Impact factor: 4.757
Authors: Matthew A Getzlaf; Eric A Lewallen; Hilal M Kremers; Dakota L Jones; Carolina A Bonin; Amel Dudakovic; Roman Thaler; Robert C Cohen; David G Lewallen; Andre J van Wijnen Journal: J Orthop Res Date: 2015-12-29 Impact factor: 3.494
Authors: Jiri Gallo; Ales Panacek; Robert Prucek; Eva Kriegova; Sarka Hradilova; Martin Hobza; Martin Holinka Journal: Materials (Basel) Date: 2016-05-05 Impact factor: 3.623
Authors: Kevin Staats; Florian Sevelda; Alexandra Kaider; Christoph Böhler; Irene K Sigmund; Stephan E Puchner; Reinhard Windhager; Johannes Holinka Journal: Infection Date: 2017-10-24 Impact factor: 3.553